2024 ASH Annual Meeting
Editors of Blood Cancers Today highlight the latest developments in hematologic malignancies presented at the 2024 ASH Annual Meeting.
Nicole Grieselhuber, MD, PhD on results of SEA-CD70 treatment in patients with high-risk MDS.
Drs. Thomas LeBlanc, Jamie Koprivnikar, and Andrew Brunner give their predictions for the future of MDS management.
Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma.
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
Exploring the latest advancements in myelofibrosis research with Kapila Viges, MD and John Mascarenhas, MD.
Two experts discuss the role of surrogate end points in MPN clinical trials.
Dr. Patel discusses PFS and MRD negativity results from the CARTITUDE-4 trial of cilta-cel versus standard of care in MM.
Jeff P. Sharman, MD, discusses pivotal findings from the phase III BRUIN CLL-321 trial.
Dr. Callander discusses a study on selinexor, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Jeff P. Sharman, MD, explores unmet needs, prognosis, and novel treatments like pirtobrutinib in CLL.
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
CAR-T achieves favorable responses and survival in relapsed or refractory LBCL in both the second- and third-line setting.
The therapy under evaluation by two ongoing studies involves a new accelerated CAR T-cell product manufacturing process.
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
There may be a link between obesity and how myeloproliferative neoplasms develop, research shows.
Rahul Banerjee, MD, of the Fred Hutchinson Cancer Center, discusses notable studies in myeloma presented at ASH 2024.
ASH recognized exemplary hematologist oncologists at the Announcement of Awards Ceremonies at the 66th Annual Meeting.
First-line, fixed-duration ibrutinib plus venetoclax provides durable PFS and OS for patients with CLL.
Venetoclax plus obinutuzumab demonstrates superior safety and efficacy compared with FCR and BR in untreated CLL.
Fewer patients in the acalabrutinib group experienced treatment-emergent cardiovascular medical events after BTKi initiation.
Marginal zone lymphoma lacks extensive research on its real-world treatment patterns and economic impact.
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
Overall survival is improved in patients with SF3B1del5q-mutated MDS when lenalidomide is sequenced before luspatercept.
Findings from a phase II trial study of patients with MDS highlight the clinical benefits and safety profile of enasidenib.
Ceralasertib is a novel oral ataxia telangiectasia and Rad3-related inhibitor for patients with myelodysplastic syndromes.
Benefits were observed of flonoltinib maleate in myelofibrosis were observed regardless of prior JAK inhibitor exposure.
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
Harinder Gill, MBBS, MD et al deems bomedemstat/ruxolitinib safe and tolerable for second-line MDS treatment.
Patients in a phase 1 study saw remarkable symptom improvements with INCB057643 and tolerated treatment well.
Hispanic ethnicity and prior transplants mismatched unrelated donors were prognostic of worse outcomes in older MF patients.
A trial in progress, phase 3 IMpactMF trial, investigates the encouraging efficacy/safety of imetelstat in MF.
The presence of genetic mutations and specific cytopenias emerged as key predictors of progression in MDS.
The phase 3 COMMANDS trial results underscore the potential longer-term clinical benefits of luspatercept in lower-risk MDS.
Phase 2 results of AZA-VEN in acute myeloid leukemia shows an efficacy benefit.
New findings underscore the potential of single-cell analyses in the unbiased unraveling of disease mechanisms in MDS.
Results from the phase 1 Combala study show the benefit of luspatercept and erythropoiesis-stimulating agents in MDS.
The phase 3 EPO-PRETAR trial demonstrates importance of early administration of ESAs in patients with MDS and anemia.
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Encouraging initial study findings in mice will inform the design of a BHB supplementation trial in human patients.
Results from the TRANSCEND CLL 004 show continued benefit of lisocabtagene maraleucel for R/R CLL treatment.
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Odronextamab achieved high ORR and CR rates in patients with relapsed or refractory third line FL
Acalabrutinib, umbralisib, and ublituximab treatment is effective in patients with de novo MCL, with a 100% CR rate.
Fixed-duration epcoritamab with rituximab plus lenalidomide drives deep and durable responses in follicular lymphoma.
Odronextamab monotherapy showed promising efficacy in patients with high-risk, grade 1-3a follicular lymphoma.
Robust responses with favorable safety has been demonstrated with tisagenlecleucel in relapsed or refractory Fl.
Favorable preclinical outcomes were demonstrated with VX765 treatment.
Upfront treatment with fixed-duration subcutaneous mosunetuzumab demonstrated a high complete response rate in FL and MZL.
Phase 1 study results hint response durability for novel CAR-T agent, CAR22 in certain patients with large B-cell lymphoma.
A study stresses psychological support as an essential component of comprehensive cancer care.
Good local control over five years using a very low dose approach was possible for potentially curable patients.
A phase I/II first-in-human study evaluates a new bivalent small molecule in relapsed or refractory FL and MZL.
Study investigated if high Vulnerable Elders Survey scores were associated with changes in quality of life across age groups.
Molecular features typically associated with inferior outcomes did not significantly affect survival or CAR-T response.
Liso-cel plus ibrutinib demonstrates substantial efficacy, deep remissions, and manageable safety.
Although liso-cel has a higher total cost than mosunetuzumab, it provides increased survival and reduced time toxicity.
Patients treated with tisa-cel, axi-cel, or liso-cel had an ORR of 65% and a one-month CR rate of 46%.
CD19-directed CAR-T therapy led to improved survival in patients with transformed follicular lymphoma.
A team of researchers investigated this mechanism of therapy resistance specifically to CD19-directed CAR T-cell therapy.
In the EPCORE CLL‑1 trial's expansion and optimization cohorts, no patients discontinued therapy due to CRS, ICANS, or ...
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.